The company said, “Ceribell (CBLL) expects revenue for the full year 2026 to be in the range of $111 million to $115 million, representing growth of approximately 25% to 29% over the company’s prior year revenue.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBLL:
- CBLL Earnings this Week: How Will it Perform?
- Ceribell: Strong Clinical Integration and AI-Driven Differentiation Support Buy Rating and High-Growth Outlook
- Ceribell: Expanding Neurology Platform, Growing TAM, and Attractive Valuation Support Buy Rating
- Ceribell: Breakthrough Stroke Detection and Expanding EEG Indications Underscore Attractive Multi‑Year Buy Opportunity
- Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool